Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 5:2022:6548945.
doi: 10.1155/2022/6548945. eCollection 2022.

Plasma Methylated RNF180 for Noninvasive Diagnosis of Gastric Cancer

Luyao Zhao  1   2 , Yandi Liu  2 , Shiwu Zhang  3 , Muran Li  2
Affiliations

Plasma Methylated RNF180 for Noninvasive Diagnosis of Gastric Cancer

Luyao Zhao et al. Biomed Res Int. .

Abstract

Background: RNF180 is a tumor suppressor gene involved in cell development, proliferation, and apoptosis. Methylation of RNF180 (mRNF180) leads to low expression of RNF180, which is closely related to the occurrence and development of gastric cancer (GC). This study was designed to evaluate the potential performance of plasma mRNF180 as noninvasive biomarker for the diagnosis of GC.

Methods: A total of 156 participants, including 60 patients with GC, 39 with chronic superficial gastritis (CSG), 27 with chronic atrophic gastritis (CAG), and 30 with gastric ulcer (GU) were recruited for this study. Plasma mRNF180 level was measured using real-time polymerase chain reaction.

Results: As a diagnostic target, mRNF180 had a sensitivity of 71.67% (95% CI: 58.36%-82.18%) and specificity of 59.38% (95% CI: 48.85%-69.14%). The area under the ROC curve value of mRNF180 was 0.731 (95% CI: 0.648%-0.813%) for differentiation of GC from benign gastric diseases (BGD). The effectiveness of mRNF180 was superior to that of CEA, CA199, and CA724. mRNF180 was positively correlated with age, tumor size, T stage, N stage, M stage, and clinical stage of patients with GC.

Conclusions: Plasma mRNF180 might serve as a useful and noninvasive biomarker for the diagnosis of GC and can be used to evaluate its prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Positive rate and mean ΔCt value of mRNF180 in each enrolled group. (a) Positive detection rate of mRNF180 for each enrolled group. Positive detection rate was compared by the χ2 test or Fisher exact test. (b) The mRNF180 mean ΔCt value for each enrolled group. Mean ΔCt value was compared by t-test. The mRNF180 ΔCt cut-off value = 9.21 was calculated by the Youden index. GC: gastric cancer; CSG: chronic superficial gastritis; CAG: chronic atrophic gastritis; GU: gastric ulcer.
Figure 2
Figure 2
ROC curve of mRNF180 and serum tumor markers. The mRNF180 had an AUC of 0.731, CEA had an AUC of 0.583, CA199 had an AUC of 0.606, and CA724 had an AUC of 0.621. AUC (RNF180) > AUC (CA724) > AUC (CA199) > AUC (CEA).
Figure 3
Figure 3
Positive rates of mRNF180 and serum tumor markers in the GC group. Positive detection rate was compared by McNemer test. ns: not significant.
Figure 4
Figure 4
Correlations between mRNF180 and clinicopathological characteristics of the GC group. Clinicopathological characteristics include sex, age, tumor location, tumor size, T stage, M stage, N stage, clinical stage, and differentiation. (a) Positive detection rate was compared by the χ2 test or Fisher exact test. (b) Mean ΔCt value was compared by t-test or F test. ns: not significant.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians . 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Oba K., Paoletti X., Bang Y. J., et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Journal of the American Medical Association . 2010;49(7):1565–1577. - PubMed
    1. Suzuki H., Oda I., Abe S., et al. High rate of 5-year survival among patients with early gastric cancer undergoing curative endoscopic submucosal dissection. Gastric Cancer . 2016;19(1):198–205. doi: 10.1007/s10120-015-0469-0. - DOI - PubMed
    1. Liang Y., Wang W., Fang C., et al. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer. Oncotarget . 2016;7(31):49565–49573. doi: 10.18632/oncotarget.10391. - DOI - PMC - PubMed
    1. Kanwal R., Gupta K., Gupta S. Cancer epigenetics: risk assessment, diagnosis, treatment, and prognosis. Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment, and Prognosis . 2014;1238:1–799.

MeSH terms

-